T cell receptors bind structurally different peptides, possibly explaining why immunotherapy for the treatment of cancer at times attacks healthy cells
A new challenge for immunotherapy discovered - cancer science short news

In the quest for efficient and safe immunotherapies for the treatment of cancer, researchers stumbled upon a surprising way some of the immune cells, the T cells, react with antigens. It appeared that the T cell receptor can bind two distinctively different peptide antigens, showing that T cell receptors can be much more cross-reactive (less specific) than previously though. This is worrisome, because this could be at the basis of why immunotherapy sometimes doesn’t only attack cancer cells, but also healthy cells. These new findings should be incorporated into immunotherapy design platforms, and more research is needed to appreciate the full consequences of this surprising observation, scientists say.

Read the full story: University of Notre Dame
Scientific publication: Nature Chemical Biology